Litcius/Paper detail

Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study

Noa Biran, Andrew Ip, Jaeil Ahn, Ronaldo C. Go, Shuqi Wang, Shivam Mathura, Brittany Sinclaire, Urszula Bednarz, Michael Marafelias, Eric Hansen, David S. Siegel, André Goy, Andrew L. Pecora, Ihor S. Sawczuk, Lauren Koniaris, Micky Simwenyi, Dániel Varga, Lisa Tank, Aaron A Stein, Valerie Allusson, George S Lin, William F Oser, Roman Tůma, Joseph Reichman, Louis Brusco, Kim Carpenter, Eric J. Costanzo, Vincent Vivona, Stuart L. Goldberg

2020The Lancet Rheumatology296 citationsDOIOpen Access PDF

Topics & Concepts

TocilizumabObservational studyCoronavirus disease 2019 (COVID-19)MedicineIntensive care unitSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakEmergency medicineIntensive care medicineVirologyInternal medicineOutbreakRheumatoid arthritisDiseaseInfectious disease (medical specialty)COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study | Litcius